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ABSTRACT
DXZ4 is an X-linked macrosatellite composed
of 12–100 tandemly arranged 3-kb repeat units.
In females, it adopts opposite chromatin ar-
rangements at the two alleles in response to
X-chromosome inactivation. In males and on the
active X chromosome, it is packaged into hetero-
chromatin, but on the inactive X chromosome (Xi),
it adopts a euchromatic conformation bound
by CTCF. Here we report that the ubiquitous tran-
scription factor YY1 associates with the euchro-
matic form of DXZ4 on the Xi. The binding of YY1
close to CTCF is reminiscent of that at other
epigenetically regulated sequences, including sites
of genomic imprinting, and at the X-inactivation
centre, suggesting a common mode of action in
this arrangement. As with CTCF, binding of YY1 to
DXZ4 in vitro is not blocked by CpG methylation,
yet in vivo both proteins are restricted to the
hypomethylated form. In several male carcinoma
cell lines, DXZ4 can adopt a Xi-like conformation
in response to cellular transformation, charac-
terized by CpG hypomethylation and binding of
YY1 and CTCF. Analysis of a male melanoma cell
line and normal skin cells from the same individual
confirmed that a transition in chromatin state
occurred in response to transformation.
INTRODUCTION
Now that most of the human genome sequence has been
assembled (1), one of several pressing issues is to deter-
mine the role of the various DNA elements in establishing
and maintaining the gene-expression proﬁles that underlie
different cell types. Because only a relatively small portion
of the genome actually codes protein (2), about half
is composed of repetitive DNA (1), and a signiﬁcant
fraction is transcribed into non-coding RNA (3), many
challenges lie ahead. Intriguing aspects of the human
genome are the extensive variation among individuals in
copy number (copy-number variation, CNV) (4) and the
consequences associated with such diversity.
Macrosatellites are an extreme form of CNV. They
are composed of individual repeat units, typically >1kb
in size, that are arranged in tandem, often spanning
hundreds of kilobases (5). Some are chromosome
speciﬁc, such as ZAV at chromosome 9q32 (6) and
DXZ4 at chromosome Xq23 (7,8), whereas others are
found on at least two chromosomes, such as D4Z4 on
chromosomes 4q35 and 10q26 (9,10) or RS447 on
chromosome 4p15 and 18p23 (11). The macrosatellite
about which most is known is D4Z4, because of its
association with onset of facioscapulohumeral muscular
dystrophy (FSHD) (12). FSHD, the third most common
inherited form of muscular dystrophy (OMIM 158900), is
primarily manifested as progressive muscle atrophy of the
face, shoulders and upper arms and is often accompanied
by gradual spread of symptoms to the lower body (13).
D4Z4 is a tandem array of as many as 100 3.3-kb repeat
units. Contraction of the macrosatellite to fewer than 11
repeat units on a permissive chromosomal haplotype (14)
is associated with disease onset (15). Recent data implicate
an altered chromatin structure for the contracted array
(16–18) and stabilization of transcripts originating from
the distal edge of the macrosatellite as the molecular
basis of the disease (19). Collectively, these data highlight
the importance of macrosatellite CNV for disease
susceptibility.
Primary DNA-sequence conservation of the X-linked
macrosatellite DXZ4 is restricted to higher primates
(20). In humans it is composed of as few as 12 to over
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many other macrosatellites (6,21,22), DXZ4 is expressed
(8,23), but unlike that of D4Z4 (24) its transcript contains
no obvious conserved open reading frames. X-linkage
exposes DXZ4 to the process of X-chromosome inactiva-
tion (XCI), a form of dosage compensation employed by
mammals to balance the levels of X-linked gene expression
in the two sexes (25). Early in female development, one
of the two X chromosomes is chosen to become the future
inactive X chromosome (Xi) (26). Soon thereafter
most gene expression from the Xi is shut down (27), and
silencing is stably maintained as the chromosome is
repackaged into facultative heterochromatin (28).
Although most of the X chromosome adopts this new
chromatin structure, DXZ4 does not conform and
instead adopts a more euchromatic organization charac-
terized by CpG hypomethylation (7,23), dimethylation of
histone H3 at lysine residue 4 (H3K4me2), acetylation
of histone H3 at lysine 9 (H3K9Ac), and association
with the epigenetic organizer protein CCCTC-binding
factor (CTCF) (23). In contrast, DXZ4 on the active
X chromosome (Xa) and male X is organized into con-
stitutive heterochromatin characterized by CpG
hypermethylation (7,23), trimethylation of histone H3 at
lysine 9 (H3K9me3) (23) and association with heterochro-
matin protein 1 gamma (HP1g) (18). Intriguingly, DXZ4
shows several parallels with the mouse X-inactivation
centre (Xic), a region of the X chromosome required
for XCI (26). These include differential CpG methylation
(29,30), transcription of non-coding RNAs (26), a tandem
repeat sequence (30) and association with Ctcf (31). In
addition, the ubiquitous zinc-ﬁnger protein Yin-Yang 1
(YY1) associates with the Xic (32).
Here, we report work showing that YY1 associated
with DXZ4 speciﬁcally on the Xi alongside CTCF.
Although in vitro CpG methylation was unable to block
YY1 binding, YY1 and CTCF were restricted in vivo to
the hypomethylated DXZ4 allele on the Xi. Furthermore,
we report changes to DXZ4 chromatin on the male X as a
result of cell transformation.
MATERIALS AND METHODS
Antibodies
Commercial primary antibodies used in this study were
obtained from the following sources: mouse anti-CTCF
(612149), BD Biosciences. Rabbit anti-CTCF (07–729),
rabbit anti-H3K4me2 (07–030) and rabbit
anti-H3K9me3 (07–523), Millipore. Rabbit anti-GAPDH
(sc-25778), goat anti-YY2 (Sc-47637) and rabbit anti-YY1
(sc-1703), Santa Cruz Biotechnology. Rabbit anti-YY1
(AB1, AV38301). Sigma-Aldrich. Commercial secondary
antibodies used in this study, Alexa Fluor-488 goat
anti-rabbit (A11001) and Alex Fluor-555 goat anti-mouse
(A21422), were obtained from Invitrogen Corporation.
Cells and cell lines
Human telomerase-immortalized female retinal pigment
epithelia (hTERT-RPE1), female mammary epithelia
(hTERT-HME1) and male foreskin ﬁbroblasts
(hTERT-BJ1) were all originally obtained from
Clontech. All are now available from the American
Type Culture Collection (ATCC). Primary male skin
ﬁbroblast cells CCD1139Sk (CRL-2708) and Malme-3
(HTB-102) were obtained from ATCC. The following
cell lines were all obtained from ATCC: female cervical
adenocarcinoma cell line HeLa (CCL-2); Malme-3M
(HTB-64), derived from a male malignant melanoma;
male hepatocellular carcinoma cell line HepG2
(HB-8065); male ﬁbrosarcoma cell line HT-1080
(CCL-121); male colorectal adenocarcinoma cell lines
SW620 (CCL-227), SW480 (CCL-228), HCT-15
(CCL-225), DLD-1 (CCL-221), Caco-2 (HTB-37),
HCT116 (CCL-247) and SW1116 (CCL-233). All cells
were maintained according to the supplier recommenda-
tions. Tissue-culture media and supplements were
purchased from Invitrogen Corporation.
Immunoﬂuorescence and ﬂuorescence in situ hybridization
Cells were grown directly on glass microscope slides
before indirect immunoﬂuorescence. They were washed
with 1  phosphate-buffered saline (PBS) before ﬁxation
and extraction in ﬁxative for 10min (1  PBS, 0.1% Triton
X-100, 3.7% formaldehyde). Cells were washed twice with
1  PBS before being blocked for 30min (3% bovine
serum albumin, BSA; 1  PBS; 0.1% Tween-20) and
were then washed three times for 2min each in 1  PBS
before incubation for 60min with the primary antibody
(1:100 dilution of primary antibody in 1  PBS, 0.1%
Tween-20, 1% BSA). Cells were washed as above before
incubation with the secondary antibody (1:100 dilution
of secondary antibody in 1  PBS, 0.1% Tween-20,
1% BSA), then washed once more and ﬁxed as
above before two washes of 2min in 1  PBS and
addition of anti-fade-containing 40,6-diamidino-2-
phenylindole (DAPI). All steps were performed at room
temperature.
Indirect immunoﬂuorescence combined with ﬂuores-
cence in situ hybridization (FISH) was performed as
above with the following additional steps before applica-
tion of DAPI. Cells were dehydrated for 3min each in
70% and 100% ethanol before being air-dried. Dried
cells were denatured in 70% formamide, 2  saline–
sodium citrate buffer (2  SSC; pH 7.0) for 10min at
83 C, before dehydration in ice-cold 70% and 100%
ethanol for 3min each and air-drying. A Spectrum
Orange direct-labeled DXZ4 probe was prepared by nick
translation in the presence of Spectrum Orange dUTP ac-
cording to the manufacturer’s instructions (Abbot
Molecular). The DXZ4 probe was resuspended in
Hybrisol VII (MP Biomedicals) and denatured at 78 C
for 5min before being placed on ice. The probe was
applied to the cells and sealed under a cover-slip with
rubber cement and incubated overnight at 37 Ci na
humidiﬁed chamber. The following day, the cells were
washed twice for 8min each in 50% formamide, 2  SSC
at 42 C, then washed once for 8min in 2  SSC at 42 C,
before being mounted in DAPI.
Imaging was performed on a DeltaVision pDV. The
images were deconvolved with softWoRx 3.7.0 (Applied
Nucleic Acids Research,2012, Vol.40, No. 4 1597Precision) and compiled with Adobe Photoshop CS2
(Adobe Systems).
Chromatin immunoprecipitation
Cells were ﬁxed in culture media for 10min at room tem-
perature by addition of formaldehyde to 1% ﬁnal concen-
tration. Cross-linking was quenched for 5min by addition
of glycine to 125mM ﬁnal concentration. Cells were
washed and collected with ice-cold 1  PBS supplemented
with 0.1mg/ml phenylmethylsulfonyl ﬂuoride. Cells were
resuspended at 7 10
 6 cells/ml in lysis buffer (1% SDS,
10mM EDTA, 50mM Tris, pH 8.0, containing 2mg/ml
Aprotinin, 2mg/ml Leupeptin, 1mg/ml Pepstatin and
0.1mg/ml phenylmethylsulfonyl ﬂuoride). Chromatin
was sheared with a Bioruptor (Diagenode) set at high
power, 30s on, 30 s off. Sonication was performed with
0.2ml of lysate per 1.7-ml tube for 12 cycles; the bath was
cooled with ice every fourth cycle. Lysate was precleared
with protein-A agarose beads, before addition of primary
antibody and incubation overnight at 4 C. Immune
complexes were collected the next day with protein-A
agarose and washed at 4 C twice for 5min each with
low wash buffer (0.1% SDS, 1% Triton X-100, 2mM
EDTA, 150mM NaCl, 20mM Tris, pH 8.0), once for
5min with high wash buffer (0.1% SDS, 1% Triton
X-100, 500mM NaCl, 20mM Tris, 8.0) and once for
5min with TE buffer (10mM Tris, pH 8.0, 1mM
EDTA). Protease inhibitors were used at the same concen-
tration as in the lysis buffer. Chromatin was eluted at
room temperature with 100mM NaHCO3, 1% SDS and
cross-links reversed overnight at 65 C after addition of
NaCl to 0.2M. Residual RNA was removed for 30min
at 37 C with RNase A, then protein by a 120-min incu-
bation at 42 C with proteinase K. DNA was puriﬁed with
the QIAquick PCR puriﬁcation kit (Qiagen). Protein-A
agarose, RNase A, proteinase K and all protease inhibi-
tors were obtained from Roche Applied Science.
DNA immunoprecipitated with either CTCF or YY1
was assessed by PCR with DXZ4-F23 (GGACAGTCCC
AAGCCACTC) and DXZ4-R26 (AGATGCTGATCCG
CCATGTG). DNA immunoprecipitated with either
H3K4me2 or H3K9me3 was assessed by PCR with
DXZ4-F19 (GAGATGCCCATGAACTCAAG) and
DXZ4-R19 (GCCAGGGGGATAGGTGTG). All oligo-
nucleotides we used were obtained from Euroﬁns MWG
Operon.
Electrophoresis mobility shift assays
Whole-cell extracts were prepared from HeLa S3 cells as
described previously (33), with the exception that phos-
phatase inhibitors were not included. Oligonucleotides
were generated to the following DNA sequences along
with oligonucleotides to the complementary strand:
DXZ4-YY1 (CGCCCCGCACATGGCGGATCAG),
DXZ4-YY1-Mut (CGCCCCGCATTGGGCGGA
TCAG), DXZ4-YY1L (GGAAAAAACGCCAACAGC
GCCCCGCACATGGCGGATCAG). We labeled the
double-stranded oligomers radioactively with
T4-polynucleotide kinase (New England Biolabs) in the
buffer designated by the manufacturer and (g-
32P) ATP
(Perkin Elmer-Cetus). HeLa whole-cell extracts were
incubated with the
32P-labeled double-stranded oligomers
on ice for 30min in binding buffer (10mM Tris, pH 7.5,
50mM NaCl, 1mM DTT, 5% glycerol), in the presence of
1mg dIdC and 1mg of non-speciﬁc double-stranded DNA
oligomers. The protein-DNA complexes were then
separated on 4% polyacrylamide gels and ﬁxed for
15min (10% acetic acid, 10% methanol) before drying.
Dried gels were exposed to a phosphoimager screen and
scanned with a Typhoon 9410 Imager (GE Healthcare,
Piscataway, NJ, USA). We assayed competition by
adding cold oligomers and performed supershifts by
adding speciﬁc anti-YY1, anti-YY2, or non-speciﬁc
antibody (anti-GAPDH) to the binding reactions, as
indicated. Using double-stranded DXZ4-YY1L as a
template, we methylated the C’s of CpG dinucleotides in
the sequence with M.SssI according to the manufacturers’
recommendations (New England Biolabs). Methylation
was assayed with the methyl-sensitive restriction endo-
nuclease HinP1I (New England Biolabs). Both methylated
and non-methylated DXZ4-YY1Ls were then used in
mobility-shift assays as described above. Oligonucleotides
modiﬁed with 5-methyl Cytosine were synthesized directly
with the same sequence as DXZ4-YY1 above; only the
three C’s in the CpG context were methylated for the
forward and reverse sequence (Euroﬁns MWG Operon).
Nuclear extracts from HeLa cells stably overexpressing
Flag-epitope tagged YY1 (33) and puriﬁcation of bacter-
ially expressed non-tagged YY1 protein (34) have been
described previously.
Bisulﬁte analysis
Genomic DNA was isolated from cells with the Qiagen
Blood and Cell Culture DNA Midi Kit (Qiagen, Valencia,
CA, USA). Bisulﬁte modiﬁcation was performed with the
Qiagen EpiTect Bisulﬁte Kit according to the manufactur-
er’s instructions. We performed PCR using the primers
DXZ4-Bis-F1 (CCAAACAAACTACCCAAAACC) and
DXZ4-Bis-R2 (GAAGGTAGGTTAGTAAGAAGG),
which amplify a 535-bp fragment of modiﬁed DXZ4.
PCR products were cloned into pDrive with the Qiagen
PCR cloning kit. Plasmid DNA was isolated from clones
and DNA sequence was supplied by the sequencing
services of Euroﬁns MWG Operon.
RESULTS
The Xi is the largest mass of facultative heterochromatin
in a female nucleus; at interphase it is typically located at
the nuclear periphery in a structure called the Barr body
(35). Because many chromatin proteins and euchromatin
associated histone modiﬁcations are underrepresented in
or absent from the Barr body, the territory of the Xi
appears as a hole in the distribution pattern obtained
when immunoﬂuorescence is performed with antibodies
to any of these chromatin features (36). Because DXZ4
is packaged into euchromatin and bound by CTCF on the
Xi (23), immunoﬂuorescence for either CTCF or
H3K4me2 readily detects an intense focus within the ter-
ritory of the Xi, a pattern that is shared with several other
1598 Nucleic Acids Research, 2012,Vol.40, No. 4DXZ4-associated proteins and chromatin modiﬁcations
(36).
YY1 associates with DXZ4 on the inactive X chromosome
In our indirect immunoﬂuorescence assays, YY1 showed a
general nuclear staining pattern with an obvious
underrepresentation at the Xi except at a single intense
focus (Figure 1). Consistent with previous data (23,36),
CTCF showed a general nuclear distribution and a dot
within the Barr body. Interestingly, the Xi-associated
YY1 and CTCF signals overlapped.
The combination of YY1 immunoﬂuorescence with
FISH with a direct-labeled DXZ4 probe indicated that
the Xi-associated YY1 signal overlapped with DXZ4
(Figure 2A), but examination of the DXZ4 signal
originating from the Xa showed little to no overlap with
DXZ4, suggesting that YY1 association with DXZ4 is Xi
speciﬁc.
To validate the immunoﬂuorescence and FISH data
and to conﬁrm that YY1 is actually binding to DXZ4
and not simply near it, we performed chromatin
immunoprecipitation (ChIP) using anti-YY1 on several
Figure 1. Examples of indirect immunoﬂuorescence performed with anti-YY1 (H-414, sc-1703), showing the distribution of YY1 (green) and CTCF
(red) in female hTERT-RPE1 nuclei on the inactive X chromosome. The 40,6-diamidino-2-phenylindole (DAPI) images are shown in black and white,
which better emphasize the densely staining Barr body. The white arrow-head points to the intense CTCF and YY1 signal within the territory of the
Barr body. The bottom panel is a third example zoomed in to show more clearly that YY1 overlaps with the CTCF signal.
Nucleic Acids Research,2012, Vol.40, No. 4 1599independent male and female cell cultures. When the
immunoprecipitated DNA was assessed by PCR with
primer sets covering subregions of a single 3-kb DXZ4
monomer (data not shown), only one primer set, encom-
passing a 186-bp fragment of DXZ4, consistently
generated a product for the YY1 ChIP, a result that was
only observed for the female samples. Figure 2B shows
examples for two independent male samples (left panels)
and two female samples (right panels). YY1 is therefore
associated with DXZ4 on the Xi only.
YY1 binds to a histone alpha-like consensus sequence in
DXZ4
When the 3-kb DNA sequence of a single DXZ4 repeating
unit was examined for putative YY1-binding sites, a
match was found with the 7-bp alpha element (37), a
YY1-binding motif located in the coding region–
activating sequence of the H2A.2 and H3.2 histone
genes (38) (Figure 3A). Importantly, this sequence motif
resides within the 186-bp sequence that is positive for YY1
ChIP. Alignment of the alpha element match with the
DNA sequence of 60 different DXZ4 monomers from
nine independent sources (8) revealed that the motif is
100% conserved (data not shown).
When double stranded DNA oligomers were generated
for the 22-bp DXZ4 sequence shown in Figure 3A and
labeled with
32P, electrophoresis mobility shift assays
(EMSA) revealed a clear shift in mobility in the presence
of whole-cell extract. The shift could be speciﬁcally
reduced in the presence of excess unlabeled oligomer but
not when binding competition was performed with oligo-
mers of which the core CAT sequence had been mutated
(39) (Figure 3B, left four lanes). Binding in the presence of
one of two independent anti-YY1 antibodies, but not with
a non-speciﬁc antibody, resulted in a supershift of the
labeled DNA, conﬁrming that YY1 in the cell extract is
binding to the predicted site in DXZ4 (Figure 3B, right
three lanes).
In humans, a retrotransposed homolog of YY1 termed
YY2 resides at Xp22.1–22.2 (40). It shares >95%
amino-acid identity across the zinc-ﬁnger DNA-binding
domain of YY1 (40) and recognizes similar DNA
sequence motifs (41). Using a YY2 antibody, we did not
see a supershift for the DXZ4 YY1 target site (Figure 3C).
This result suggests that the shift that we do see is
generated by YY1. Data supporting YY1 binding to
DXZ4 in vitro are shown in Figure 3B, where an
antibody raised to a portion of the amino-terminus of
YY1 that is less well conserved in YY2 (AB1) shows a
supershift comparable to that for antibodies raised to
full-length YY1.
Binding of YY1 to its target sequence in DXZ4 is not
affected by CpG methylation in vitro
Collectively these data support Xi-speciﬁc association of
YY1 with DXZ4, at a site <80 nt from the Xi-speciﬁc
CTCF-binding site (23). Like YY1, CTCF is a
multi-zinc-ﬁnger DNA-binding protein with important
roles in epigenetic regulation of gene expression and chro-
matin organization (42). At a number of genomic sites,
Figure 2. YY1 associates with DXZ4 on the Xi only. (A) Examples of
female hTERT-RPE1 nuclei showing the distribution of YY1 by
indirect immunoﬂuorescence (green) combined with direct DNA ﬂuor-
escence in situ hybridization with a probe for DXZ4 (red).
DAPI-stained nuclei are shown in black and white, which better em-
phasize the Barr body (left column). The small white arrow indicates
the location of DXZ4 on the active X chromosome. The white arrow-
head indicates DXZ4 on the inactive X chromosome. The bottom sets
of panels are a close-up of an image. Overlapping signals appear
orange. (B) YY1 ChIP output assessed for DXZ4 association by
PCR. Two male samples are shown on the left (top, hTERT-BJ1;
bottom, CCD1139Sk) and two female samples on the right (top,
hTERT-HME1; bottom, hTERT-RPE1). Samples assessed include the
input (IN), eluted immunoprecipitation (IP) and an immunopre-
cipitation with non-speciﬁc rabbit serum (RS). PCR results shown
use DXZ4-F23 and DXZ4-R26. Immunoﬂuorescence and ChIP were
performed with anti-YY1 (H-414, sc-1703). These results show that
YY1 associates with DXZ4 on the inactive X chromosome only.
1600 Nucleic Acids Research, 2012,Vol.40, No. 4including imprinted regions, binding of CTCF to DNA is
impaired by CpG methylation (43–46). In contrast, CTCF
binding to its DXZ4 target site in vitro is not affected by
CpG methylation (23), perhaps because the CTCF site in
DXZ4 does not directly contain any CpG residues.
Binding of YY1 to DNA is reported to be impaired by
CpG methylation at some sites (47) but not at others (48).
The YY1-binding site in DXZ4 contains one CpG di-
nucleotide within the central 7-bp motif and several at
other CpG sites nearby (Figure 3D). Previously, we have
determined that these CpG sequences are largely
methylated both in males and on the Xa, whereas the
same sites are unmethylated on the Xi (23)
(Supplementary Figure S1). We therefore sought to deter-
mine whether methylation of the YY1-binding site was
sufﬁcient to block binding and hence to restrict YY1 to
the Xi.
A double-stranded 39-bp sequence encompassing the
YY1-binding site and three upstream CpG dinucleotides
was generated as the target for methylation sensitive
EMSA (Figure 3D). One CpG dinucleotide resides
within a recognition sequence (GCGC) for HinP1I, a re-
striction endonuclease unable to digest target sites when
the central CpG is methylated. Using this feature as a
measure of complete methylation, we methylated the
CpG sites in the 39-bp oligomer in vitro using M.SssI.
Methylated and unmethylated oligomers were then sub-
jected to HinP1I digestion, which conﬁrmed that the
oligomer was fully methylated (Figure 3E). The EMSA
experiment was then repeated with either the methylated
or unmethylated target sequence. As can be seen in Figure
3F, methylation of the target site appears to have had no
effect on YY1 binding, so like CTCF, which binds the
methylated form of its DXZ4-binding site in vitro (23),
YY1 requires more than just DNA methylation to
prevent binding to DXZ4 on the Xa in vivo.
The clear blocking of HinP1I digestion of the
methylated double-stranded oligonucleotide (Figure 3E)
does not conﬁrm efﬁcient methylation of the other CpG
dinucleotides in the DNA fragment. To complement this
Figure 3. YY1 electrophoresis mobility-shift assays (EMSA). (A)
Alignment of the candidate YY1-binding sequence of the macrosatellite
DXZ4 (top) with two other well characterized YY1 binding consensus
sequences. The core CAT element is highlighted. Below the alignments
is the synthesized mutant (Mut.) sequence that no longer contains the
CAT motif that was used in the EMSA. (B) Phosphoimager output of a
dried EMSA gel. Radioactive bands appear dark. Samples loaded in
each lane are labeled across the top and include speciﬁc competition
(SC) and non-speciﬁc competition (NSC). Supershift analysis is shown
in the last three lanes to the right with two independent YY1 antibodies
and a non-speciﬁc control. The locations of the shift (S) and supershift
(SS) are indicated by the arrowheads to the right of the gel. Free probe
(FP) is indicated at the bottom of the gel. (C) Supershift analysis with
anti-YY1 and anti-YY2. (D) Extended DNA sequence ﬂanking the
YY1 core CAT element (highlighted in black). CpG dinucleotides
are highlighted by the dots below the sequence, and the location of
the HinP1I site is highlighted in gray (GCGC). (E) Agarose gel (4.0%)
analysis showing results of HinP1I digestions of the DNA sequence
shown in (C), each of which was ﬁrst treated or not with M.SssI,
which methylates CpG dinucleotides in vitro. Presence or absence of
either enzyme in the procedure is indicated above the corresponding
lanes of the gel by the plus or minus symbol. DNA size is indicated to
the right by a 10-bp ladder. (F) Phosphoimager output of a dried
EMSA gel with the DNA sequence shown in (C). Radioactive bands
appear dark. Target DNA sequence that has not (left two samples) or
has been (right two samples) treated with M.SsspI before analysis is
indicated above the gel by plus and minus symbols. Inclusion of
whole-cell extract is indicated below. The location of the shift is
indicated by the small black right-facing arrows. (G) Methylation in-
sensitivity and YY1 speciﬁcity EMSA. EMSA shows shift with HeLa
nuclear extract (Extract), a molecular weight shift for Flag-epitope-
tagged YY1 from nuclear extract from HeLa cells overexpressing
YY1-Flag (Extract Flag-YY1), and shift with puriﬁed non-tagged
YY1 from bacteria (Puriﬁed YY1). Analyses are shown side by side,
non-methylated double-stranded oligonucleotides to the left and
CpG-methylated ones to the right. The arrows to the right of the gel
indicate the Flag shift (top) and non-tagged shift (bottom).
Nucleic Acids Research,2012, Vol.40, No. 4 1601analysis, we therefore synthesized a sense and anti-sense
oligonucleotide, corresponding to the DXZ4 sequence
shown in Figure 3A, in which the three Cs in the CpG
context were methylated. Side-by-side analysis of the
unmethylated and methylated double-stranded oligo-
nucleotides revealed no impact on the ability of endogen-
ous YY1, Flag-tagged YY1, or bacterially puriﬁed YY1 to
bind to the sequence (Figure 3G). These data conﬁrm not
only that methylation of CpG does not block YY1
binding in vitro but also that YY1 is responsible for the
EMSA as demonstrated by the shift corresponding to the
Flag-tagged YY1 and a shift with puriﬁed YY1.
YY1 and CTCF bind to the hypomethylated form of
DXZ4 on the active X chromosome in some male
carcinomas
Changes in DNA methylation are a common feature in
cancer (49), affecting both unique and repetitive compo-
nents of the genome. Indeed, in various cancers, increases
and decreases in DNA methylation have been reported
for large tandem-repeat DNA such as D4Z4 and NBL-2
(50–52). To date, changes in CpG methylation at DXZ4 in
cancer have not been investigated. Although CpG methy-
lation does not block binding of YY1 (Figure 3E)
or CTCF (23) to their DXZ4 target sites in vitro, both
proteins are restricted in vivo to the hypomethylated
macrosatellite on the Xi. Previously, we and others have
shown that most DXZ4 CpG dinucleotides are methylated
in males (7,23), so we investigated a number of male car-
cinoma cell lines for a reduction in DXZ4 methylation
by bisulﬁte sequencing with the premise that any such re-
duction in methylation might result in altered accessibility
of YY1 and CTCF to DXZ4.
Across the interval encompassing the bidirectional
promoter and binding sites for YY1 and CTCF, three
independent colon carcinoma cell lines (HCT15, Caco-2
and SW1116) had CpG methylation proﬁles indistin-
guishable from those of normal males (23) (Figure 4A)
(Supplementary Figure S1). Notably, two CpG residues
frequently appear resistant to methylation (CpG-11 and
less frequently CpG-30 from the left) in normal human
males (23) (Supplementary Figure S1), as well as in
pig-tailed macaque DXZ4 (20). The CpG-11 resides ap-
proximately midway between the YY1 and CTCF-binding
sites and CpG-30 within the deﬁned promoter. The rele-
vance of these largely methylation-resistant CpGs is not
obvious but is intriguing.
A fourth colon-carcinoma cell line (DLD-1) also shows
a typical male CpG methylation proﬁle at DXZ4 (Figure
4B) and more importantly has a proﬁle similar to that of
HCT-15 (Figure 4A); the two cell lines are believed to be
derived independently from the same cancer specimen
(53,54), so any differences in methylation proﬁles are
unlikely to result from cell-line derivation. In contrast, a
ﬁfth colon-carcinoma cell line (HCT116) and a ﬁbrosar-
coma cell line (HT-1080) show lower methylations—only
16.2 and 52.1% CpG methylation, respectively
(Figure 4B).
To investigate changes to chromatin organization at
DXZ4, we performed ChIP on HCT116 and HT-1080
along with DLD-1 (Figure 4C). As in male primary cells
(23), the heterochromatin marker H3K9me3 was detected
in all three samples. The euchromatin marker H3K4me2
could readily be detected at DXZ4 in HCT116 and
HT-1080, conﬁrming a euchromatic organization of the
macrosatellite consistent with the CpG hypomethylation
proﬁle (Figure 4B). Low levels of H3K4me2 could also
be detected in DLD-1, possibly because DXZ4 is ex-
pressed at varying levels in males (8,23) and this signal
might therefore represent transcriptionally active DXZ4
monomers.
Transformation-associated chromatin changes at DXZ4
allow CTCF and YY1 to bind DXZ4 on the active X
chromosome
Next we sought to determine what changes, if any, occur
to the methylation proﬁle and chromatin organization of
DXZ4 in association with metastasis and transformation.
First we determined and compared the DXZ4 CpG
methylation proﬁle of SW480, established from a
primary colon adenocarcinoma, with that of SW620,
derived from a metastatic lesion at a later stage of
colon carcinoma in the same individual (55). In this
instance the methylation proﬁles were very similar;
overall CpG methylation was slightly higher in SW620
(Figure 4D), suggesting no dramatic alteration in DXZ4
chromatin organization. Then we examined the CpG
methylation proﬁle of DXZ4 in skin primary ﬁbroblasts
(Malme-3) and a cell line derived from a malignant
melanoma from the same individual (Malme-3M).
DXZ4 CpG methylation for Malme-3 was comparable
to that seen in other normal male ﬁbroblasts
(Supplementary Figure S1) (79.4%), whereas a reduction
in methylation was noticeable in the melanoma cell line
(64.1%) (Figure 4E). ChIP, intended to explore possible
chromatin changes associated with the reduced DNA
methylation at DXZ4, once again revealed low levels of
the euchromatic marker H3K4me2 in the primary male
ﬁbroblast cells (Figure 4F). This result was not too
surprising given that >20% of CpG residues in the
interval are unmethylated (Figure 4E) and that low
levels of H3K4me2 could be detected in DLD-1, a
male sample with higher overall CpG methylation
(Figure 4C), but when CTCF was used to mark a shift
from the male X/Xa arrangement toward a female
Xi-like organization, CTCF could only be detected in
the melanoma cell line (Figure 4F), consistent with our
observations for carcinoma cell lines HT-1080 and
HCT116 (Figure 4C). Furthermore, we detected binding
of YY1 to DXZ4 in Malme-3M but not in Malme-3
(Figure 4F). The low YY1 signal in Malme-3M may
arise because the YY1-binding region retains overall
higher methylation than is seen in HCT116 and
HT-1080 (compare Figure 4B with E), suggesting that
CpG methylation affects YY1 binding to DXZ4
in vivo. Importantly, this result shows that transform-
ation was associated with a reduction in CpG methyla-
tion and a gain of CTCF and YY1 binding at DXZ4 in
this individual.
1602 Nucleic Acids Research, 2012,Vol.40, No. 4Figure 4. DXZ4 CpG methylation and chromatin structure in male carcinomas and transformation-associated changes. (A) Schematic representation
(top) of a single 3-kb DXZ4 monomer shown right to left on the basis of the orientation on Xq. The region assessed for CpG methylation is
highlighted, and the coordinates for the interval ampliﬁed with the forward and reverse primers given above the monomer. Region of interest
(bottom) expanded to show the location of the promoter along with the CTCF and YY1-binding sites. The line below it shows the location of all
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(continued)Predicting DXZ4 CpG methylation proﬁle from
euchromatic chromatin signatures and CTCF association
with the macrosatellite
Our data support a model in which DXZ4 on the Xa and
male X is packaged into constitutive heterochromatin
characterized by H3K9me3 and CpG methylation. In
contrast, DXZ4 on the Xi is largely packaged into eu-
chromatin characterized by H3K4me2 and CpG
hypomethylation and is bound by YY1 and CTCF.
Transformation-associated reduction in DNA methyla-
tion at the macrosatellite, however, alters the chromatin
organization sufﬁciently to permit binding of YY1 and
CTCF to male DXZ4, shifting it into a more Xi-like
state. On the basis of this model, we would predict that
observation of YY1 or CTCF at DXZ4 in male cells
would indicate an overall hypomethylated CpG state. To
test this hypothesis, we examined the chromatin proﬁle for
CTCF at DXZ4 using the publicly available Encode data
from ChIP experiments combined with high-throughput
sequencing (56).
Consistent with our observations (23), DXZ4 in normal
female but not male cells is characterized by the presence
of euchromatic markers H3K4me2 and histone H3
lysine-9 acetylation (H3K9Ac) and binding of CTCF
(Figure 5A), but in the male hepatocellular carcinoma
cell line HepG2, DXZ4 chromatin organization is indis-
tinguishable from the female proﬁles. Analysis of the CpG
methylation status of DXZ4 in HepG2 cells reveals a
hypomethylated state comparable to that of HCT116
and HT-1080 (Figure 5B), supporting transformation-
associated changes to DXZ4 chromatin organization on
the male X chromosome.
DISCUSSION
DXZ4 is an enigmatic DNA element that adopts a chro-
matin organization different from that of the ﬂanking
chromosome: largely heterochromatin on the Xa and eu-
chromatin bound by CTCF on the Xi (23). Here, we
report that the zinc-ﬁnger protein YY1 associates specif-
ically with the euchromatic form of DXZ4 alongside
CTCF on the Xi. Colocalization of YY1 and CTCF has
been reported at binding sites within tandem repeat DNA
at autosomal imprinted loci (57) and the Xic (32). The
theme that uniﬁes these three situations is that all are
classic examples of epigenetics—maintenance of two
alleles in alternate chromatin states—and support a
model in which chromatin marked by YY1 and CTCF
in close proximity has an important role in establishing
and/or maintaining an alternate chromatin organization
on one chromosome.
In vitro analysis showed that both YY1 and CTCF (23)
can bind methylated DXZ4 target sequences, yet in vivo
neither is detected at such sequences. Therefore, methyla-
tion alone cannot account for the allelic exclusion of either
protein. One explanation could be that in vivo methylated
DXZ4 DNA is inaccessible. Given that the DXZ4
macrosatellite on the Xa and in males is packaged in con-
stitutive heterochromatin characterized by H3K9me3 (23)
and HP1g (18), this supposition is not unreasonable.
Indeed, binding of CTCF and YY1 does closely follow
the methylation proﬁle of DXZ4, as demonstrated by
the binding of both proteins to hypomethylated DXZ4
in two independent male carcinoma cell lines (HCT116
and HT-1080) (Figure 4C), and a malignant melanoma
cell line, but not in primary skin cells from the same
male (Figure 4F), and CTCF binding to the
hypomethylated macrosatellite in HepG2 cells (Figure
5A). Interestingly, these independent male cancer-cell
lines showed a shift of DXZ4 chromatin organization
from a typical Xa state toward one that more closely
resembled that on the Xi in females. Conceivably, this
arrangement is the default for DXZ4, and in these
samples it is reverting back toward this base state. If so,
we would predict that DXZ4 in pluripotent cells would
exist in a euchromatic arrangement, a hypothesis we are
actively pursuing.
Our in vitro data indicate that YY1 bound to DXZ4,
but given that YY2 recognizes similar DNA sequence
motifs (41) and possesses a near identical DNA binding
domain (40), YY2 may also be associating in vivo with
DXZ4. Because YY1 and YY2 are not functionally redun-
dant and can mediate antagonistic effects at target sites
(58,59), possible binding of YY2 at DXZ4 warrants
further investigation.
YY1 has also been shown to associate with the chromo-
some 4q macrosatellite D4Z4 (60), extending the parallels
between this disease-associated macrosatellite and DXZ4
Figure 4. Continued
CpG dinucleotides, represented by the circles on sticks. Below the schematic map are the methylation proﬁles for three different male colon
carcinoma cell lines. Each horizontal row of 36 circles represents the sequencing result of an independent TA clone from cloning of PCR
products generated from bisulﬁte-modiﬁed DNA template for the corresponding cell lines. Methylated CpGs are represented by ﬁlled circles,
unmethylated ones by open circles. Sequence variations at DXZ4 that result in a non-C at a consensus CpG site are represented by dashes. CpG
dinucleotides contained in the YY1-binding site and promoter are indicated above each proﬁle. The upward-facing arrowheads indicate the
commonly hypomethylated CpG residues CpG-11 and CpG-30. The percentage methylation is given in brackets beside each name. (B)
Representation as in (A) showing CpG methylation proﬁles for two other male colon-carcinoma cell lines and one male ﬁbrosarcoma cell line.
(C) ChIP analysis of DXZ4 chromatin for the male cell line shown immediately to the left in (B). Data are shown for H3K4me2, H3K9me3, CTCF,
and YY1 as indicated to the right of each agarose gel image and are representative examples from three independent ChIP replicates for each cell
line. Samples assessed include the input (IN), the eluted immunoprecipitation (IP), and an immunoprecipitation with non-speciﬁc rabbit serum (RS).
YY1 and CTCF were assessed with DXZ4-F23 and DXZ4-R26, whereas H3K4me2 and H3K4me3 were assessed with DXZ4-F19 and DXZ4-R19.
ChIP was performed with anti-YY1 (sc-1703). (D) Representation as in (A) showing CpG methylation proﬁles for a cell line derived from a primary
colon adenocarcinoma (SW480) and a metastatic lesion at a later stage of colon carcinoma in the same individual (SW620). (E) Representation as in
(A) showing CpG methylation proﬁles from a male normal skin ﬁbroblast culture (top) and a malignant melanoma cell line from the same individual
(bottom panel). (F) Analysis as in (C) showing H3K4me2, H3K9me3, CTCF and YY1 ChIP data for the samples shown immediately on the left in
(E). Data are representative examples from two independent replicate ChIP experiments.
1604 Nucleic Acids Research, 2012,Vol.40, No. 4(61), but in this instance, YY1 is associated, as part of a
repressor complex (60), with the normal heterochromatic
form of D4Z4, and CTCF only associates upon contrac-
tion in FSHD (17) when D4Z4 reverts toward a more
euchromatic conformation (18). Whether YY1 remains
associated with D4Z4 in its euchromatic contracted form
remains to be determined.
Collectively, these data provide novel insight into the
organization and stability of chromatin at the
macrosatellite DXZ4. Further parallels can be drawn
Figure 5. Correlation between CpG methylation and chromatin organization of DXZ4. (A) The ChIP-Seq proﬁle for part of the DXZ4
macrosatellite [Encode histone modiﬁcations by Broad Institute ChIP Seq (64)]. The locations of individual 3-kb monomers are marked by left-facing
arrows. The boxed shaded area in each arrow indicates the region containing the promoter and binding sites for CTCF and YY1. Below are the
ChIP-Seq proﬁles for CTCF, H3K4me2, and H3K9Ac as indicated to the right. Proﬁles include the male hepatocellular carcinoma cell line HepG2;
two independent normal female lines [top, lymphoblastoid cell line (GM12878); bottom, human mammary epithelial cells (HMEC)]; and two
independent normal males [top, human skeletal-muscle myoblasts (HSMM); bottom, human umbilical-vein endothelial cells (HUVEC)]. The
image was taken from the UCSC genome browser (http://genome.ucsc.edu) and shows data taken with default settings from genome build hg18,
showing a 10-kb window; coordinates X; 114881001–114891000. The data shown in all tracks are the signal view and used the default scale of 0–50
as indicated to the left. (B) Schematic representation (top) of a single 3-kb DXZ4 monomer shown as a left-facing arrow. The region assessed for
CpG methylation is indicated by the shaded region and the coordinates given. Methylation proﬁle (bottom) of this interval for HepG2. Methylated
CpGs are represented by ﬁlled circles, unmethylated ones by open circles. Sequence variations at DXZ4 that result in a non-C at a consensus CpG
site are represented by dashes. The percentage methylation is given to the left of the proﬁle.
Nucleic Acids Research,2012, Vol.40, No. 4 1605between DXZ4 and D4Z4, as well as monoallelic chroma-
tin states at sites of genomic imprinting and the Xic.
The ability of DXZ4 to adopt two distinct chromatin
states in the context of XCI (7,20,23), in the absence of
the macrosatellite contraction gain of function seen for
D4Z4 in FSHD (17,18), strongly suggests that DXZ4
fulﬁls, through epigenetic regulation, two alternate
conserved (20) functions on the X chromosome—one
packaged as heterochromatin on the Xa and the other in
a euchromatic conformation of the Xi. Although only the
XIC located at Xq13 is required for XCI in humans (62),
DXZ4 may still have some role after XCI in spreading the
XCI signal or facilitating organization of the Xi. Recent
data from Joen and Lee (63) indicate that Yy1 possesses
both DNA and RNA-binding activities and physically
tethers Xist RNA to the Xi. This exciting result is a
major step forward in deciphering how Xist associates ex-
clusively with the Xi. Xist spreads in cis along the length
of the Xi (28), so numerous other Xist entry sites deﬁned
by Xi-speciﬁc Yy1 might facilitate this process. The
Xi-speciﬁc association of YY1 at DXZ4 could function
to assist in the spread of XIST along the length of the
chromosome.
Macrosatellites remain a perplexing and largely unex-
plored aspect of our genome (5). We anticipate that fu-
ture studies will reveal that these DNA elements occupy
an important niche in genome regulation and disease
susceptibility.
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